What Continuum Health Ventures does

Continuum Health Ventures (CHV) is a thesis-driven early-stage venture capital fund founded in 2021 with offices in Toronto and Silicon Valley and approximately $200 million in committed capital. The fund invests across Healthtech, Techbio, and Healthspan Extension (Longevity) startups, with a stated mission focused on prevention, precision intervention, and reversing disease hallmarks associated with aging. Its stated geographic reach centers on the United States but extends globally to Canada, the EU, the Middle East, India, Japan, Korea, and Singapore.

The fund's product surface is its portfolio: 12 disclosed portfolio companies spanning AI-powered diagnostics (ViewsML, JIVI AI), FDA-cleared medical devices (Ampa Health's Ampa One brain stimulation system), infectious disease genomics (Biotia), healthcare AI infrastructure (BeekeeperAI's EscrowAI), consumer biomarker testing (Function Health), digital therapeutics (DeepWell DTx, Enara Health), biotech and secretome biologics (Immunis, Cardiatech Bio), and general-purpose humanoid robotics with healthcare applications (Sanctuary AI's Phoenix). Notable portfolio technical components include AI-driven virtual biomarker staining from H&E pathology images, zero-trust confidential computing for HIPAA-compliant PHI, reinforcement learning for dexterous robotic manipulation, and secretome-based biologics in FDA Phase 1/2a trials. The fund states 326 worldwide partners across payors, providers, pharma, devices, and consumer tech to support commercialization.

CHV's business model follows standard 2-and-20 venture economics, generating revenue through management fees on committed capital and carried interest on portfolio exits. The team comprises two General Partners (Ricky Mehra, Daniel Kraft M.D.), one Venture Partner (Michael Apkon M.D.), a Senior Advisor (Dick Foster), Entrepreneurs in Residence, a Big Data Architect, Fellows, and several domain advisors. Go-to-market is direct equity investment through seed and Series A rounds, often as a co-investor alongside other healthcare-focused funds. Distribution and deal-sourcing leverage include a graduate-student Fellowship program launched in 2025, media positioning through CNN features, and participation in regional deep-tech showcases.

Name

Continuum Health Ventures

Legal name

Continuum Health Ventures

Website

https://continuumhealth.vc

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Continuum Health Ventures is a thesis-driven early-stage venture capital fund with $200M in committed capital, investing in Healthtech, Techbio, and Healthspan Extension (Longevity) startups across the US, Canada, EU, and Asia from offices in Toronto and Silicon Valley.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525), Finance and Insurance (52)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital fund
• Healthtech investing
• Longevity capital
• Seed stage funding
• Techbio investment

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Returns: Standard VC fund model generating returns through management fees on committed capital and carried interest on portfolio company exits. The fund has $200M in capital to deploy across early-stage investments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Continuum Health Ventures is an early-stage venture capital fund that deploys equity capital from a $200M pool into startups focused on Healthtech, Techbio, and Healthspan Extension (Longevity). The firm pairs capital investment with active operational support and market access through a 326-partner network spanning payors, providers, pharma, device, and consumer tech. Its primary thesis targets the convergence of health and technology, with a focus on prevention, aging biology, and digitizing healthcare.

Product overview

Continuum Health Ventures is an early-stage venture capital fund that seeds and accelerates Healthtech, Techbio, and Healthspan Extension (Longevity) startups. The firm's portfolio consists of 12 portfolio companies offering diverse health technology products: ViewsML (AI-powered virtual biomarker staining from pathology images), Ampa One (FDA-cleared portable brain stimulation device), Sanctuary AI Phoenix (general machine intelligence humanoid robot with healthcare applications), Function Health (comprehensive biomarker testing membership service), JIVI AI (clinical AI agentic platform with MedX and HealthOS), Enara Health (obesity management digital platform), DeepWell DTx (video game-based mental health digital therapeutics), BeekeeperAI (zero-trust healthcare AI collaboration platform with EscrowAI), Biotia (AI-powered infectious disease detection via NGS), Immunis (secretome biologics for age-related conditions), and Cardiatech Bio (multiomics-based cardiovascular drug discovery). These products span AI-powered diagnostics, medical devices, digital therapeutics, biotechnology, and robotics platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-Stage Venture Capital Investment Equity capital deployment into early-stage Healthtech, Techbio, and Healthspan Extension (Longevity) startups at seed and Series A stages, paired with active operational support and market access through a 326-partner network.
• CHV Fellowship Program Fellowship program offering exceptional graduate students direct exposure to cutting-edge ventures in Digital Health and Longevity, including company pitches and connection with industry leaders.

Named customers11 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability13 records

Partnerships

One partnership is on record.

• Edmonton UnlimitedminorStrategic or Co-development Partner · 9 June 2026Continuum Health Ventures participated as a VC panelist at Edmonton Unlimited's showcase event supporting deep tech commercialization for local Alberta entrepreneurs.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ARCH Venture Partners: ARCH is a leading US venture firm focused on early-stage life sciences, biotech, and healthcare companies, similar in thesis-driven sector focus to CHV but with materially larger AUM and a longer track record across techbio and digital health.
• OrbiMed: OrbiMed is one of the largest healthcare-focused investment firms globally, spanning venture, growth, and public equity. It is broadly comparable to CHV as a sector-specialist in healthtech and biotech, though at vastly greater scale and with longer-duration funds.
• Andreessen Horowitz (Bio + Health Funds): A16z's dedicated Bio and Healthcare funds invest across healthtech, biotech, and digital health from seed to growth - the same convergence zone CHV targets, but with substantially more capital, brand, and partner headcount.
• Founders Fund: Founders Fund invests across deep tech including healthcare-adjacent areas like biotech, longevity, and neurotechnology. Its willingness to back frontier health and life-extension theses overlaps with CHV's 'healthspan extension' mandate.

Direct peers

• Khosla Ventures: Khosla Ventures is a thesis-driven, sector-agnostic firm with deep conviction bets at the intersection of technology and biology/Health. Its willingness to back unconventional healthtech and longevity theses (including AI diagnostics and biotech platforms) makes it one of the closest analogs to CHV's mandate.
• Lux Capital: Lux Capital is a sector-focused early-stage venture firm investing in frontier technology and health/bio. Like CHV, it backs bold techbio and healthtech theses from seed to Series A and emphasizes founder empathy and technical depth among its partners.
• Section 32: Section 32 is a healthcare-only venture fund investing across digital health, biotech, and techbio. Its pure-play healthcare focus and similar stage orientation make it a direct functional comparable to CHV, with overlapping portfolio categories.
• Bold Capital Partners: Bold Capital Partners is a thesis-driven early-stage investor with explicit focus on longevity, healthspan, and techbio. Its dedicated longevity thesis and comparable fund size make it one of the closest thematic analogs to CHV.

Emerging players

• Petri Ventures: Petri (formerly Petri Bio) is an emerging player focused on bioengineering and the intersection of biology with technology. Like CHV, it is a smaller specialist that bets early on bioconvergence theses - a comparable emerging-stage analog.
• Magnetic Ventures: Magnetic Ventures is an emerging early-stage fund specializing in human health, longevity, and biotech. Its exclusive focus on healthspan and adjacent techbio aligns directly with CHV's stated mandate at a similar fund size stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Continuum Health Ventures